Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Giardia lamblia | Nitric oxide synthase, inducible | 0.0262 | 0.8717 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0149 | 0.4402 | 0.4402 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0147 | 0.4316 | 1 |
Loa Loa (eye worm) | flavodoxin family protein | 0.0113 | 0.3033 | 0.3033 |
Leishmania major | cytochrome P450 reductase, putative | 0.0262 | 0.8717 | 0.8717 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0113 | 0.3033 | 0.5 |
Trypanosoma cruzi | Flavodoxin/Radical SAM superfamily/Wyosine base formation, putative | 0.0113 | 0.3033 | 0.3033 |
Treponema pallidum | flavodoxin | 0.0113 | 0.3033 | 1 |
Trypanosoma brucei | S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase, putative | 0.0113 | 0.3033 | 0.3033 |
Plasmodium falciparum | NADPH--cytochrome P450 reductase, putative | 0.0113 | 0.3033 | 0.3033 |
Brugia malayi | FAD binding domain containing protein | 0.0183 | 0.5684 | 0.5684 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0113 | 0.3033 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0183 | 0.5684 | 0.5684 |
Brugia malayi | flavodoxin family protein | 0.0113 | 0.3033 | 0.3033 |
Trypanosoma cruzi | Flavodoxin/Radical SAM superfamily/Wyosine base formation, putative | 0.0113 | 0.3033 | 0.3033 |
Plasmodium falciparum | S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase, putative | 0.0113 | 0.3033 | 0.3033 |
Giardia lamblia | Hypothetical protein | 0.0262 | 0.8717 | 1 |
Plasmodium vivax | hypothetical protein, conserved | 0.0113 | 0.3033 | 0.3033 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0183 | 0.5684 | 0.5684 |
Echinococcus multilocularis | methionine synthase reductase | 0.0183 | 0.5684 | 0.5684 |
Trypanosoma cruzi | NADPH--cytochrome P450 reductase, putative | 0.0113 | 0.3033 | 0.3033 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0113 | 0.3033 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0113 | 0.3033 | 0.3033 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0147 | 0.4316 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.0183 | 0.5684 | 1 |
Echinococcus granulosus | methionine synthase reductase | 0.0183 | 0.5684 | 0.5684 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0262 | 0.8717 | 0.8717 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0113 | 0.3033 | 0.5 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0113 | 0.3033 | 0.5 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0262 | 0.8717 | 0.8159 |
Schistosoma mansoni | diflavin oxidoreductase | 0.0147 | 0.4316 | 0.4316 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 5.2213 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 10 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 70.7946 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.